-

Agilent Names Simon May to Lead Diagnostics and Genomics Group

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced Simon May has been named president of the company’s Diagnostics and Genomics Group (DGG). May, previously executive vice president and president of the Life Science Group at Bio-Rad Laboratories, will join Agilent on May 6.

“We are excited to welcome Simon May to the Agilent team,” said Padraig McDonnell, COO and CEO-elect. “Simon’s deep technical knowledge, his broad range of experience, and his career-long focus on strategy, continuous improvement and operational excellence are critical additions to our DGG organization as we capitalize on the opportunities that lie in front of us in helping our customers bring great science to life.”

Prior to his role with the Life Science Group, Simon served in other positions at Bio-Rad, including senior vice president and general manager of the Digital Biology Group, and as senior vice president of Global Commercial Operations. Before joining Bio-Rad in 2014, May held positions at Thermo Fisher Scientific for 10 years as well as MWG Biotech. He began his career in laboratory roles before moving into sales, product-management, and business-leadership positions.

May earned his bachelor’s degree and his doctorate in genetics/molecular biology from England’s University of Liverpool, where he later spent two years as a postdoctoral research fellow.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers’ most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Media Contact:
Tom Beermann
+1 408-386-5892
tom.beermann@agilent.com

Investor Contact:
Parmeet Ahuja
+1 408-345-8948
parmeet_ahuja@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions
$Cashtags

Contacts

Media Contact:
Tom Beermann
+1 408-386-5892
tom.beermann@agilent.com

Investor Contact:
Parmeet Ahuja
+1 408-345-8948
parmeet_ahuja@agilent.com

More News From Agilent Technologies Inc.

Agilent to Participate in 9th Annual Evercore Healthcare Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the company will participate in the upcoming 9th Annual Evercore Healthcare Conference. Agilent management is scheduled to participate in a fireside chat from 10 a.m. to 10:50 a.m. EST on Tuesday, Dec. 1, 2026, in Coral Gables, Florida. A live audio webcast and replay of the presentation will be available through Agilent’s Investor Relations website. About Agilent Technologies Agilent Technologies Inc...

Agilent Expands Tumor Profiling Portfolio with SureSelect Cancer Research Pan Heme

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the SureSelect Cancer Research Pan Heme, a hybrid capture-based next-generation sequencing (NGS) research solution for comprehensive genomic profiling of hematologic malignancies. Developed in collaboration with experts at Roswell Park Comprehensive Cancer Center, the solution integrates DNA and RNA profiling, automated sample preparation and bioinformatics in a streamlined workflow. The introduction of Su...

Agilent Completes Acquisition of Proscia

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the successful completion of its previously announced acquisition of Proscia®, a leading provider of digital-pathology software for clinical and life-sciences customers. Under the terms of the transaction, Agilent acquired Proscia for $240 million in cash at closing, with up to an additional $30 million payable based on the achievement of future performance milestones. Following the closing of the transact...
Back to Newsroom